Marksans Pharma Limited (MARKSANS.BO)
INR 314.2
(-2.1%)
INR 314.2
(-2.1%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.9 Billion INR | 189.27% |
| 2022 | 656.89 Million INR | 58.54% |
| 2021 | 414.34 Million INR | 344.28% |
| 2020 | 93.26 Million INR | 24.01% |
| 2019 | 75.2 Million INR | -24.8% |
| 2018 | 100 Million INR | 0.0% |
| 2017 | 100 Million INR | -9.09% |
| 2016 | 110 Million INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | -100.0% |
| 2013 | 198.15 Million INR | 151.57% |
| 2012 | 78.76 Million INR | -48.18% |
| 2011 | 152.01 Million INR | -20.01% |
| 2010 | 190.04 Million INR | -95.52% |
| 2009 | 4.24 Billion INR | 6.93% |
| 2008 | 3.96 Billion INR | 17.36% |
| 2007 | 3.37 Billion INR | 6.01% |
| 2006 | 3.18 Billion INR | 4.89% |
| 2005 | 3.03 Billion INR | 238.55% |
| 2004 | 897.53 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 610.49 Million INR | 0.0% |
| 2023 FY | 1.9 Billion INR | 189.27% |
| 2023 Q4 | 1.9 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 656.89 Million INR | 0.0% |
| 2022 FY | 656.89 Million INR | 58.54% |
| 2022 Q2 | 497.27 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q4 | 414.34 Million INR | 0.0% |
| 2021 Q2 | 30.58 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 414.34 Million INR | 344.28% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 179.77 Million INR | 0.0% |
| 2020 Q4 | 93.26 Million INR | 0.0% |
| 2020 FY | 93.26 Million INR | 24.01% |
| 2019 FY | 75.2 Million INR | -24.8% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 100 Million INR | 0.0% |
| 2019 Q4 | 75.2 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 100 Million INR | 0.0% |
| 2018 Q2 | 188.74 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 100 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 100 Million INR | -9.09% |
| 2017 Q4 | 100 Million INR | 0.0% |
| 2017 Q3 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2016 FY | 110 Million INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2016 Q4 | 110 Million INR | 0.0% |
| 2016 Q3 | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2015 Q3 | - INR | 0.0% |
| 2015 Q2 | - INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | - INR | -100.0% |
| 2014 Q3 | 118.85 Million INR | -17.05% |
| 2014 Q2 | 143.29 Million INR | 0.0% |
| 2014 FY | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 65.46 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 198.15 Million INR | 0.0% |
| 2013 FY | 198.15 Million INR | 151.57% |
| 2012 FY | 78.76 Million INR | -48.18% |
| 2012 Q2 | 231.46 Million INR | 0.0% |
| 2012 Q4 | 78.76 Million INR | 0.0% |
| 2011 FY | 152.01 Million INR | -20.01% |
| 2010 FY | 190.04 Million INR | -95.52% |
| 2009 FY | 4.24 Billion INR | 6.93% |
| 2008 FY | 3.96 Billion INR | 17.36% |
| 2007 FY | 3.37 Billion INR | 6.01% |
| 2006 FY | 3.18 Billion INR | 4.89% |
| 2005 FY | 3.03 Billion INR | 238.55% |
| 2004 FY | 897.53 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott India Limited | 367.6 Million INR | -416.918% |
| Cipla Limited | 2.25 Billion INR | 15.704% |
| Gland Pharma Limited | 1.06 Billion INR | -78.355% |
| GlaxoSmithKline Pharmaceuticals Limited | 64.69 Million INR | -2837.333% |
| Kopran Limited | 166.02 Million INR | -1044.507% |
| NGL Fine-Chem Limited | 7.44 Million INR | -25412.755% |
| Pfizer Limited | 543.5 Million INR | -249.621% |
| Sanofi India Limited | 139 Million INR | -1267.043% |
| SMS Pharmaceuticals Limited | 1.22 Billion INR | -55.643% |